MedTrace Logo

Probiotic Use for Recovery Enhancement From Long COVID-19

NCT06643299 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2025-09-03

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if probiotics can improve symptoms and quality of life in participants with Long COVID.

Conditions

  • Post-Acute COVID-19 Syndrome

Interventions

DRUG

Probiotic Agent

BlueBiology: Ultimate Care probiotic pill taken once daily for a four-month period.

OTHER

Placebo

Placebo produced to be identical in taste and appearance to the probiotic agent, taken once daily for a four-month period.

Sponsors & Collaborators

  • Rush University Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-13
Primary Completion
2026-05-31
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06643299 on ClinicalTrials.gov